GLP-1 weight loss estimator

See what participants in the major clinical trials lost on average, scaled to your starting weight. A trial average — not a prediction.

Starting weight

Semaglutide 2.4 mg (STEP 1)—

Semaglutide 7.2 mg — Wegovy HD (STEP UP)—

Tirzepatide 5 mg (SURMOUNT-1)—

Tirzepatide 10 mg (SURMOUNT-1)—

Tirzepatide 15 mg (SURMOUNT-1)—

Placebo + lifestyle (STEP 1)—

Trial participants also followed diet and exercise counseling and were monitored by clinicians. Individual results vary widely. Whether a GLP-1 is right for you is a decision for a licensed prescriber.

Where the numbers come from

Wilding et al., NEJM 2021 (STEP 1): mean change −14.9% with semaglutide 2.4 mg vs −2.4% with placebo at 68 weeks.
STEP UP (Novo Nordisk, 2026): mean change −18.8% with semaglutide 7.2 mg at 72 weeks regardless of adherence (−20.7% if staying on treatment).
Jastreboff et al., NEJM 2022 (SURMOUNT-1): mean change −15.0%, −19.5%, and −20.9% with tirzepatide 5, 10, and 15 mg vs −3.1% with placebo at 72 weeks.